FDA postpones public meeting on reauthorization of MDUFA for 2023 through 2027
The U.S. Food and Drug Administration (FDA) is announcing that the public meeting “Medical Device User Fee Amendments for Fiscal Years 2023 Through 2027” that was scheduled in the Federal Register on April 3, 2020 to take place on May 5, 2020 is postponed until further notice.
The purpose of this public meeting is to discuss proposed recommendations for the reauthorization of the Medical Device User Fee Amendments (MDUFA) for fiscal years 2023 through 2027. The FDA will continue to accept submit electronic or written comments on the medical device user fee program and suggestions regarding the commitments the FDA should propose for the next reauthorized program in the Federal Register Docket No. FDA-220-N-0907.
The agency continues to evaluate whether and how to proceed with upcoming scheduled meetings while their day-to-day operations are impacted by the COVID-19 public health emergency. Information about the rescheduled meeting will be provided when available.
